ad image
LANXESS successfully completes acquisition of Solvay’s phosphorus additive business

LANXESS successfully completes acquisition of Solvay’s phosphorus additive business

Feb 14, 2018PR-M02-18-NI-051

Specialty chemicals company LANXESS has successfully completed the purchase of the phosphorus chemicals business from Belgian chemicals group Solvay including its U.S. production site in Charleston, South Carolina. All relevant antitrust authorities have cleared the transaction. LANXESS and Solvay agreed to the purchase in mid-November 2017. 

The site in Charleston includes six production plants, where roughly 90 employees manufacture phosphorus chloride plus numerous derivative products such as flame-retardant additives and intermediate products for agrochemicals. The business represents annual sales of roughly EUR 65 million. 

The acquisition is another consistent step in the Group’s growth strategy with a focus on mid-sized markets and the North America and Asia regions.



Forward-Looking Statements

This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person’s officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.